Professor Scott Webster is Chair of Medicines at the Centre of Cardiovascular Science, University of Edinburgh. During his career, he has held positions in both biotech and academia. For more than a decade, he has specialised in translational research within academia focusing on discovering and developing small molecules as medicines for the treatment of diverse conditions including Alzheimer’s disease, multiple organ failure, fibrotic disease and Multiple Sclerosis. His research has led to the discovery of a number of potent small molecule modulators of target enzymes and receptors, including UE2343/XanamemTM.
He has worked across therapeutic areas and has expertise spanning protein biochemistry, pharmacology and medicinal chemistry. During his time in academia he has worked collaboratively with a number of pharmaceutical companies including GSK, AstraZeneca and Sanofi. Prof Webster is Founder and Chief Scientific Officer of Kynos Therapeutics, which is developing therapies for systemic inflammation and multiple organ failure.